Treatment with licogliflozin, a dual sodium‐glucose co‐transporter (SGLT)1/2‐inhibitor, is associated with increased stool frequency and loose stools, attributed to SGLT1 inhibition. To investigate the effect of carbohydrate content and supplements on licogliflozin‐induced stools, a randomized, open‐label, two‐part (N = 24/part), three‐period crossover study was carried out in overweight or obese adults. Significantly higher (P < 0.01) change from baseline in 3‐day total number of bowel movements was observed following 3 days of licogliflozin treatment (50 mg q.d.) together with a 50% carbohydrate meal compared with a 25% and 0% carbohydrate meal. The number of stools with Bristol Stool Chart score of 6 or 7 was also significantly lower following a 0% carbohydrate meal. Supplementation with psyllium 6 g or calcium carbonate 1 g had no effect on stool changes following treatment. Licogliflozin was generally safe and well‐tolerated. Loose stool associated with licogliflozin treatment and ingestion of meals can be managed by reducing the carbohydrate content of meals taken with licogliflozin.

中文翻译：

---

减少饮食中碳水化合物对SGLT1抑制相关的粪便频率和稠度的调查和管理：一项随机试验。

双重钠葡萄糖共转运蛋白（SGLT）1/2抑制剂licogliflozin的治疗与大便次数增加和大便稀疏有关，这归因于SGLT1的抑制作用。为了研究碳水化合物含量和补充剂对利格列净诱导的粪便的影响， 在超重或肥胖的成年人中进行了一项随机，开放标签的，分为两部分（N = 24 /部分），为期三期的交叉研究。明显更高（P 服用Licogliflozin（50 mg qd）3天后，与含25％和0％碳水化合物的膳食相比，经3天的利格列净治疗（50 mg qd），观察到肠蠕动总数从基线开始的变化小于<0.01）。碳水化合物含量为0％后，布里斯托尔凳图得分为6或7的粪便数量也显着降低。补充车前草6克或碳酸钙1克对治疗后的粪便变化没有影响。利格列净一般安全且耐受良好。与利格列净治疗和进餐相关的大便稀疏可以通过减少利格列净服用的膳食中的碳水化合物含量来控制。